Centessa Pharmaceuticals plc (CNTA)

NASDAQ: CNTA · IEX Real-Time Price · USD
-0.25 (-3.70%)
At close: Nov 27, 2023, 4:00 PM
-0.19 (-2.92%)
After-hours: Nov 27, 2023, 7:25 PM EST

Company Description

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.

Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.

The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861.

In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas.

Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Centessa Pharmaceuticals plc
Centessa Pharmaceuticals logo
Country United Kingdom
Founded 2020
IPO Date May 28, 2021
Industry Biotechnology
Sector Healthcare
Employees 75
CEO Dr. Saurabh Saha M.D., Ph.D.

Contact Details

3rd Floor, 1 Ashley Road
Altrincham, Cheshire, X0 WA14 2DT
United Kingdom
Phone 44 7391 789784
Website centessa.com

Stock Details

Ticker Symbol CNTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001847903
CUSIP Number 152309100
ISIN Number US1523091007
SIC Code 2834

Key Executives

Name Position
Dr. Saurabh Saha M.D., Ph.D. Chief Executive Officer and Director
Dr. Gregory M. Weinhoff M.B.A., M.D., MBA Principal Accounting Officer and Chief Financial Officer
Dr. Antoine Yver M.D., M.Sc., MSc Executive Vice President and Chairman of Development
Dr. Thomas S. Templeman Ph.D. Chief Technology Officer
Dr. David M. Chao Ph.D. Chief Administrative Officer
Kristen K. Sheppard Esq., J.D. Senior Vice President of Investor Relations and Corporate Communications
Iqbal J. Hussain L.L.B. General Counsel, Chief Compliance Officer and Corporate Secretary
Karen M. Anderson Chief People Officer
Tia L. Bush Chief Quality Officer
Dr. David John Grainger Ph.D. Chief Innovation Officer

Latest SEC Filings

Date Type Title
Nov 13, 2023 10-Q Quarterly Report
Nov 13, 2023 8-K Current Report
Oct 25, 2023 8-K Current Report
Sep 20, 2023 144 Filing
Sep 1, 2023 144 Filing
Aug 24, 2023 8-K Current Report
Aug 14, 2023 10-Q Quarterly Report
Aug 14, 2023 8-K Current Report
Aug 1, 2023 144 Filing
Jul 10, 2023 8-K Current Report